ClinicalTrials.gg
Active, not recruitingNCT06740526Updated Oct 27, 2026

Phase 2b Open-Label Repeat Kidney Biopsy Study

A Phase 2 interventional study of Sibeprenlimab in IgA Nephropathy, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Active, not recruiting at 19 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Updated Oct 27, 2026Now Active, not recruitingFirst sites in Argentina, Japan and United Kingdom+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Glomerulonephritis, IGA with a site in United States — 25 open to participants now, 37 under way, 16 of them phase 3. Glomerulonephritis, IGA · United States.

Enrollment
36th of 67
56 · median 67
Started
2024
with 5 others
Phase 2
30 of 73
11 open now
Primary completion
2028-12
later than 23 of 36 live
Registered
53rd of 73
by date
Lead sponsor
5 of 73
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 73 studies in Glomerulonephritis, IGA with a site in United States, this one is the 36th largest by enrollment of the 67 interventional ones that give a count, is one of 6 that started in 2024, is one of 30 in phase 2, reaches primary completion later than 23 of the 36 other live ones, and was the 53rd registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

25 of the 73 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

Assess impact of sibeprenlimab on IgA deposition and other histological endpoints in kidney tissue at Week 52 relative to baseline

03

Conditions studied

  • IgA Nephropathy
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be at least 18 years of age or older at the time of signing the /assent.
  2. Source-verified kidney confirmed diagnosis of IgAN.
  3. Participant has > 45 mL/min/1.73 m2 using serum creatinine based on CKD-EPI 2021 equation. Serum creatinine assessments for the determination of eGFR should be taken when the participant is considered to be in a steady state without recent changes in volume status, medications that could impact the result (eg, nonsteroidal anti-inflammatory drugs [NSAIDs], aminoglycosides, trimethoprim, cimetidine, pyrimethamine, fenofibrate, or creatine supplements), or changes in dietary protein intake.

Exclusion criteria

Exclusion Criteria:

  1. Participants who are breast-feeding and/or who have a positive pregnancy test result prior to receiving sibeprenlimab.
  2. Participant has coexisting chronic kidney disease, other than IgAN.
  3. Participant has a serum IgG value \<600 mg/dL at screening.
  4. Participant is currently receiving or has received within 24 weeks prior to the firstdose of sibeprenlimab, systemic or (note:

    topical, ophthalmic, rectal, intra-articular, inhaled corticosteroids are allowed).

  5. Participant has uncontrolled hypertension (defined as systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg).
  6. Participants who would be likely to require prohibited concomitant therapy during the trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Sibeprenlimab

    Drug: Sibeprenlimab

Interventions

  • Sibeprelimab SC (Period 1) Sibeprelimab SC (Period 2)

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Glomerular IgA Deposition by Immunofluorescence in Kidney Tissue to Week 52

    Time frame: From Baseline to Week 52

07

Study locations

19 sites
08

References and documents

Publications

  • Howie AJ, Lalayiannis AD. The Oxford Classification Should Remain the Gold Standard for Classification of IgA Nephropathy: CON. Kidney360. 2026 Oct 1;7(10):2382-2384. doi: 10.34067/KID.0000001083. Epub 2026 Feb 9. No abstract available. PubMed 41661687 ↗

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com

Data sharing details ↗ · clinical-trials.otsuka.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2028, 48 months after the start.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 48 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Nov 2024 → Dec 2024, primary completion Apr 2029 → Dec 2028 and completion Apr 2029 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2024
First posted
Dec 18, 2024
StartActual
Dec 5, 2024was Nov 2024
Primary completionEst.
Dec 28, 2028was Apr 2029
CompletionEst.
Dec 28, 2028was Apr 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 27, 2026
Sites
19 sites added, 5 sites removed — first sites in Argentina, Japan and United Kingdom
Show 19 added (6 United States, 6 Japan, 3 Canada, 2 Argentina, 2 United Kingdom)
  • University of Alabama at Birmingham · Birmingham, United States
  • Stanford University Medical Center · Stanford, United States
  • Colorado Kidney Care PC · Denver, United States
  • Massachusetts General Hospital (MGH) Harvard · Boston, United States
  • Dakota Dunes · Dakota Dunes, United States
  • Prolato Clinical Research Center · Houston, United States
  • Hospital Britanco de Buenos Aires · Buenos Aires, Argentina
  • Centro Medico Dra Laura Maffei- Investigacion Clinica Aplicada · Buenos Aires, Argentina
  • St. Paul's Hospital · Vancouver, Canada
  • Hamilton Centre for Kidney Research (HCKR) · Hamilton, Canada
  • OTT Healthcare · Scarborough Village, Canada
  • Juntendo University - Urayasu Hospital · Urayasu, Japan
  • Kobe University Hospital · Kobe, Japan
  • Nara Medical University Hospital · Kashihara, Japan
  • Kyushu University Hospital · Fukuoka, Japan
  • University of Miyazaki Hospital · Miyazaki, Japan
  • Juntendo University Hospital · Tokyo, Japan
  • Leicester General Hospital · Leicester, United Kingdom
  • King's College Hospital NHS Foundation Trust · London, United Kingdom
Show 5 removed
  • Clinical Research Site 330 · Denver, United States
  • Clinical Research Site 369 · Boston, United States
  • Clinical Research Site 374 · Dakota Dunes, United States
  • Clinical Research Site 324 · Houston, United States
  • Clinical Research Site 305 · Scarborough, Canada
Oct 27, 2026
Start date
Nov 19, 2024→Dec 5, 2024
Oct 27, 2026
Primary completion
Apr 17, 2029→Dec 28, 2028
Oct 27, 2026
Study completion
Apr 17, 2029→Dec 28, 2028
Oct 27, 2026
Enrollment
25 (estimated)→56 (actual)
Oct 27, 2026
Eligibility
Minimum age 16 Years→18 Years; 2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedParticipants must be at least 1618 years of age or older at the time of signing the informed consent/assent.
  • ChangedBefore Participant has estimated glomerular filtration rate (eGFR) > 45 mL/min/1.73 m2 using serum creatinine (Chronic Kidney Disease-Epidemiology Collaboration [CKD EPI] creatinine eGFR 2021 equation for those 18 years and older; Chronic Kidney Disease in Children under age 25 [CKiD U25] eGFR equation for those younger than 18 years)Now Participant has eGFR > 45 mL/min/1.73 m2 using serum creatinine based on CKD-EPI 2021 equation. Serum creatinine assessments for the determination of eGFR should be taken when the participant is considered to be in a steady state without recent changes in volume status, medications that could impact the result (eg, nonsteroidal anti-inflammatory drugs [NSAIDs], aminoglycosides, trimethoprim, cimetidine, pyrimethamine, fenofibrate, or creatine supplements), or changes in dietary protein intake.
Oct 27, 2026
Title
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue→Phase 2b Open-Label Repeat Kidney Biopsy Study
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Active, not recruiting
    19 sites added, 5 sites removed — first sites in Argentina, Japan and United Kingdom
    Show 19 added (6 United States, 6 Japan, 3 Canada, 2 Argentina, 2 United Kingdom)
    • University of Alabama at Birmingham · Birmingham, United States
    • Stanford University Medical Center · Stanford, United States
    • Colorado Kidney Care PC · Denver, United States
    • Massachusetts General Hospital (MGH) Harvard · Boston, United States
    • Dakota Dunes · Dakota Dunes, United States
    • Prolato Clinical Research Center · Houston, United States
    • Hospital Britanco de Buenos Aires · Buenos Aires, Argentina
    • Centro Medico Dra Laura Maffei- Investigacion Clinica Aplicada · Buenos Aires, Argentina
    • St. Paul's Hospital · Vancouver, Canada
    • Hamilton Centre for Kidney Research (HCKR) · Hamilton, Canada
    • OTT Healthcare · Scarborough Village, Canada
    • Juntendo University - Urayasu Hospital · Urayasu, Japan
    • Kobe University Hospital · Kobe, Japan
    • Nara Medical University Hospital · Kashihara, Japan
    • Kyushu University Hospital · Fukuoka, Japan
    • University of Miyazaki Hospital · Miyazaki, Japan
    • Juntendo University Hospital · Tokyo, Japan
    • Leicester General Hospital · Leicester, United Kingdom
    • King's College Hospital NHS Foundation Trust · London, United Kingdom
    Show 5 removed
    • Clinical Research Site 330 · Denver, United States
    • Clinical Research Site 369 · Boston, United States
    • Clinical Research Site 374 · Dakota Dunes, United States
    • Clinical Research Site 324 · Houston, United States
    • Clinical Research Site 305 · Scarborough, Canada
    Start date Nov 19, 2024→Dec 5, 2024
    Primary completion Apr 17, 2029→Dec 28, 2028
    Study completion Apr 17, 2029→Dec 28, 2028
    Enrollment 25 (estimated)→56 (actual)
    Eligibility Minimum age 16 Years→18 Years; 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipants must be at least 1618 years of age or older at the time of signing the informed consent/assent.
    • ChangedBefore Participant has estimated glomerular filtration rate (eGFR) > 45 mL/min/1.73 m2 using serum creatinine (Chronic Kidney Disease-Epidemiology Collaboration [CKD EPI] creatinine eGFR 2021 equation for those 18 years and older; Chronic Kidney Disease in Children under age 25 [CKiD U25] eGFR equation for those younger than 18 years)Now Participant has eGFR > 45 mL/min/1.73 m2 using serum creatinine based on CKD-EPI 2021 equation. Serum creatinine assessments for the determination of eGFR should be taken when the participant is considered to be in a steady state without recent changes in volume status, medications that could impact the result (eg, nonsteroidal anti-inflammatory drugs [NSAIDs], aminoglycosides, trimethoprim, cimetidine, pyrimethamine, fenofibrate, or creatine supplements), or changes in dietary protein intake.
    Title Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue→Phase 2b Open-Label Repeat Kidney Biopsy Study
    + 5 other changes: verification date, oversight details, description, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06740526
Responsible party
Sponsor
First posted
Dec 18, 2024
Start date
Dec 5, 2024
Primary completion
Dec 28, 2028 (estimated)
Completion
Dec 28, 2028 (estimated)
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sibeprenlimab

Start the discussion